A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers

Phase 1 Completed 129 enrolled Hutchison Medipharma Limited

Non-randomizedSequentialOpen-labelTreatment

Summary

An open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability, and PK of fruquintinib in patients with advanced solid tumors, metastatic colorectal cancer and metastatic breast cancer.

Timeline

Start: 2017-12-11
Primary completion: 2022-12-13
Completion: 2023-03-30

Publications

Wang-Gillam A, Schelman W, Ukrainskyj S, Chien C, Gonzalez M, Yang Z, Kania M, Yeckes-Rodin H. Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States. Invest New Drugs. 2023 Dec;41(6):851-860. doi: 10.1007/s10637-023-01395-y. Epub 2023 Oct 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fruquintinib	Small molecule	3 mg	Oral
Subject	Fruquintinib	Small molecule	5 mg	Oral

A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers

Summary

Timeline

Publications

Drugs

Indications